# Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors

> **NCT05831033** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 16 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** BEN101

## Key facts

- **NCT ID:** NCT05831033
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2027-02-15
- **Final completion:** 2027-06-15
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05831033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05831033, "Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05831033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*